Abstract 30P
Background
While the currently available KRASG12C-selective inhibitors including Sotorasib have shown promising efficacy, acquired resistance eventually occurred in most cancer patients following treatment. Blocking SHP2, one of critical upstream nodes, represents a rationalized strategy to overcome resistance. We have previously developed JAB-21822, a selective covalent KRASG12C inhibitor and JAB-3312, a selective allosteric SHP2 inhibitor, both of which have entered multiple clinical trials.
Methods
Cell growth inhibitory effect of JAB-21822 was evaluated in various human cancer cell lines, as well as Ba/F3 cells expressing different KRASG12C mutants with or without secondary point mutations that contribute to KRASG12C inhibitor resistance. Tumor growth inhibitory effect of JAB-21822 was also evaluated in cell line- and patient-derived xenografts. Using similar approaches, the effect of JAB-21822 in combination with JAB-3312 was evaluated in KRASG12C inhibitor-resistant tumor cells and xenograft models. Furthermore, RNA-seq was performed to identify genes with altered expression in KRAS12C inhibitor-resistant NCI-H358 cells compared to their parental counterparts. Expression of selected candidate genes were further confirmed by real-time PCR.
Results
As a single agent, JAB-21822 showed early potent antitumor effect both in vitro and in vivo. RNA-seq further identified potential genes involved in KRASG12C inhibitor resistance. Significantly, combination of JAB-21822 with JAB-3312 exerted synergistic effect in the KRASG12C inhibitor-resistant tumor cells and xenograft models tested.
Conclusions
JAB-21822 is a promising KRASG12C-targeting drug and, when combined with JAB-3312, can overcome adaptive resistance to KRASG12C inhibition. These preclinical data have provided rationale for our clinical trial featuring the two drugs combination in treating KRASG12C inhibitor-resistant cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jacobio Pharmaceuticals Co., Ltd.
Funding
AbbVie.
Disclosure
P. Wang, Q. Zheng, D. Kang, X. Sun, S. Zhu, Y. Wang, W. Long, Y. Lin : Financial interests, Personal, Full or part-time Employment: Jacobio Pharmaceuticals Co.
Resources from the same session
6P - Deep learning radiomics supports perioperative treatment decisions and is associated with LncRNAs in breast cancer: A multicenter study
Presenter: Yunfang Yu
Session: Poster viewing 01
7P - Predicting lymph node metastasis and molecular subtype from pathology united with genomics in breast cancer with multitask deep learning
Presenter: Zehua Wang
Session: Poster viewing 01
8P - Dismantling the role of liquid biopsy in predicting outcome of patients with early-stage breast cancer following neoadjuvant therapy: A systematic review
Presenter: Jeremiah Wijaya
Session: Poster viewing 01
9P - Development and validation of a pathogenomics model to improve the risk stratification of breast cancer: A deep learning study
Presenter: lin ruichong
Session: Poster viewing 01
10P - Enriched gut microbiota increases anticancer drug efficacy in breast cancer cell lines: A promising in vitro approach
Presenter: Selvaraj Jayaraman
Session: Poster viewing 01
11P - Preservation of intercostobrachial nerve during axillary lymph node dissection in breast cancer patients positively impacts chronic pain, sensory changes, and quality of life: Should it be the standard?
Presenter: Ajai Sasidhar
Session: Poster viewing 01
12P - Non-clinical factors influencing patient’s choice of mastectomy over breast conservation among Indian women with breast cancer
Presenter: Nivedita Sharma
Session: Poster viewing 01
13P - Hypofractionated radiotherapy in post operative breast cancer patients: 3-year clinical experience in a newly established cancer center
Presenter: Shaila Sharmin
Session: Poster viewing 01
14P - The impact of the deep inspiration breath-hold (DIBH) technique in the heart and other organ-at-risk (OAR) dose sparing in the postoperative radiotherapy to the left early breast cancer
Presenter: Hui-Ling Yeh
Session: Poster viewing 01
15P - Delays in breast cancer treatment in a tertiary hospital
Presenter: Rogelio Velasco
Session: Poster viewing 01